Associated Papers
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Shi CX et al.
Molecular Cancer Research : Mcr, 2020
PASTMUS: mapping functional elements at single amino acid resolution in human cells.
Zhang X et al.
Genome Biology, 2019
Case report: mutation analysis of primary pulmonary lymphoepithelioma-like carcinoma via whole-exome sequencing.
Xuan H et al.
Diagnostic Pathology, 2019
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.
Neggers JE et al.
Nature Communications, 2018
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T et al.
Science (new York, N.y.), 2017
Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells.
Hess GT et al.
Nature Methods, 2016
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI et al.
Blood, 2012
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE et al.
Leukemia, 2012
Using transcriptome sequencing to identify mechanisms of drug action and resistance.
Wacker SA et al.
Nature Chemical Biology, 2012
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M et al.
Leukemia, 2010
Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S et al.
The Journal of Pharmacology and Experimental Therapeutics, 2008
Select a paper to view details